12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Long-acting injectable iloperidone: Development discontinued

Titan disclosed in an SEC filing that Novartis decided to discontinue development of a long-acting, injectable formulation of iloperidone. Novartis will continue to commercialize Fanapt, an oral version of iloperidone, in the U.S. to treat schizophrenia...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >